使用FAERS数据库对与pimavanserin相关的不良事件进行了全面分析
Jun Gu1, Yucai Qu1, Yuan Shen1
1Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu 214151, China.
Journal of affective disorders
|July 19, 2024
概括
用于帕金森病精神病 (PDP) 的皮马万塞林在大型数据库分析中显示了潜在的不良事件,包括睡眠障碍和认知变化. 仔细监测患者对于安全有效的治疗至关重要.
科学领域:
- 药物监督 药物监督 药物监督
- 神经科学是一个神经科学.
- 临床药理学 临床药理学
背景情况:
- 皮马万塞林是一种选择性5-HT2A受体对抗剂,已被批准用于帕金森病精神病 (PDP).
- 了解其不良事件 (AE) 概况对于患者安全至关重要.
研究的目的:
- 通过FDA的不良事件报告系统 (FAERS) 数据库,全面分析与皮马万塞林相关的不良事件.
- 识别潜在的新出现或未被报告的不良事件.
主要方法:
- 从2016年第二季度到2023年第四季度,FAERS中AE报告的回顾性分析.
- 使用信号检测算法,包括ROR,PRR,BCPNN和EBGM,以识别统计显著的AE.
主要成果:
- 分析了30997份疑似皮马万塞林AE报告,在27个器官系统类别中确定了166个首选术语.
- 关键的副作用包括幻觉,死亡 (第二大报告),混乱状态和与剂量相关的问题.
- 发现的新潜在的副作用包括昏昏欲睡,失眠,alexithymia,好战和侵略性.
结论:
- 皮马万塞林治疗与潜在的不良事件有关,特别是睡眠障碍和认知/行为变化.
- 强调需要对接受皮马万塞林的PDP患者进行警监测和个性化治疗策略.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.0K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
482
相关概念视频
01:19Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97